Kymera Therapeutics (NASDAQ:KYMR) Earns "Overweight" Rating from Stephens

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report)'s stock had its "overweight" rating reaffirmed by investment analysts at Stephens in a report issued on Tuesday,Benzinga reports. They presently have a $60.00 price target on the stock. Stephens' price target indicates a potential upside of 37.30% from the stock's current price.

Several other equities analysts have also weighed in on KYMR. BTIG Research began coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They issued a "buy" rating and a $60.00 price objective on the stock. UBS Group decreased their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating for the company in a research note on Monday, November 4th. Wells Fargo & Company raised Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. Truist Financial restated a "buy" rating and set a $53.00 price objective (down previously from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Finally, Oppenheimer increased their target price on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an "outperform" rating in a report on Friday, September 27th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $55.06.

Kymera Therapeutics Trading Up 7.6 %

Shares of Kymera Therapeutics stock traded up $3.09 during midday trading on Tuesday, reaching $43.70. The company had a trading volume of 454,302 shares, compared to its average volume of 544,300. The stock has a fifty day simple moving average of $42.83 and a 200 day simple moving average of $44.56. Kymera Therapeutics has a 1-year low of $27.47 and a 1-year high of $53.27. The company has a market capitalization of $2.83 billion, a price-to-earnings ratio of -18.68 and a beta of 2.19.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.01. The company had revenue of $3.74 million during the quarter, compared to analysts' expectations of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business's revenue for the quarter was down 20.9% on a year-over-year basis. During the same period last year, the firm earned ($0.90) EPS. Sell-side analysts expect that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Activity

In other news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the transaction, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. This represents a 5.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 15.82% of the stock is owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of KYMR. Values First Advisors Inc. acquired a new position in shares of Kymera Therapeutics during the 3rd quarter worth about $61,000. Quarry LP bought a new position in Kymera Therapeutics during the third quarter worth about $95,000. Mirae Asset Global Investments Co. Ltd. increased its position in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock worth $114,000 after buying an additional 504 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new stake in Kymera Therapeutics in the second quarter valued at approximately $139,000. Finally, XTX Topco Ltd acquired a new stake in shares of Kymera Therapeutics in the second quarter valued at approximately $201,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.